Abstract
We have recently described the N-terminal RAS association domain family of genes, RASSF7–10. Previously, we cloned the N-terminal RASSF10 gene and demonstrated frequent methylation of the associated 5′-CpG island in acute lymphoblastic leukemia. To characterize RASSF10 gene expression, we demonstrate that in developing Xenopus embryos, RASSF10 shows a very striking pattern in the rhombencephalon (hind brain). It is also expressed in other parts of the brain and other organs. Due to the well-defined expression pattern in the brain of Xenopus embryos, we analyzed the methylation status of the RASSF10-associated 5′-CpG island in astrocytic gliomas. RASSF10 was frequently methylated in WHO grade II–III astrocytomas and WHO grade IV primary glioblastomas (67.5%), but was unmethylated in grade I astrocytomas and in DNA from age matched control brain samples. RASSF10 gene expression both at the mRNA and protein levels could be switched back on in methylated glioma cell lines after treatment with 5-aza-2′-deoxycytidine. In secondary glioblastomas (sGBM), RASSF10 methylation was an independent prognostic factor associated with worst progression-free survival and overall survival and occurred at an early stage in their development. In cell culture experiments, overexpression of RASSF10 mediated a reduction in the colony forming ability of two RASSF10-methylated glioma cell lines. Conversely, RNAi-mediated knockdown of RASSF10-stimulated anchorage-independent growth of U87 glioma cells, increased their viability and caused an increase in the cells’ proliferative ability. We generated and characterized a RASSF10-specific antibody and demonstrated for the first time that RASSF10 subcellular localization is cell-cycle dependent with RASSF10 colocalizing to centrosomes and associated microtubules during mitosis. This is the first report demonstrating that RASSF10 can act as a tumor suppressor gene and is frequently methylated in gliomas and can potentially be developed into a prognostic marker for sGBM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Chalmers AD, Welchman D, Papalopulu N . (2002). Intrinsic differences between the superficial and deep layers of the Xenopus ectoderm control primary neuronal differentiation. Dev Cell 2: 171–182.
Chen L, Johnson RC, Milgram SL . (1998). P-CIP1, a novel protein that interacts with the cytosolic domain of peptidylglycine alpha-amidating monooxygenase, is associated with endosomes. J Biol Chem 273: 33524–33532.
Dallol A, Hesson LB, Matallanas D, Cooper WN, O'Neill E, Maher ER et al. (2009). RAN GTPase is a RASSF1A effector involved in controlling microtubule organization. Curr Biol 19: 1227–1232.
Donninger H, Vos MD, Clark GJ . (2007). The RASSF1A tumor suppressor. J Cell Sci 120: 3163–3172.
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al. (2000). Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. 343: 1350–1354.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al. (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118: 469–474.
Hesson LB, Cooper WN, Latif F . (2007a). The role of RASSF1A methylation in cancer. Dis Markers 23: 73–87.
Hesson LB, Cooper WN, Latif F . (2007b). Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26: 7283–7301.
Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R et al. (2009). The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 8: 42.
Hesson LB, Krex D, Latif F . (2008). Epigenetic markers in human gliomas: prospects for therapeutic intervention. Expert Rev Neurother 8: 1475–1496.
Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher ER, Latif F . (2003). Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene 22: 461–466.
Langton PF, Colombani J, Chan EH, Wepf A, Gstaiger M, Tapon N . (2009). The dASPP-dRASSF8 complex regulates cell-cell adhesion during Drosophila retinal morphogenesis. Curr Biol 19: 1969–1978.
Lock FE, Underhill-Day N, Dunwell T, Matallanas D, Cooper W, Hesson L et al. (2010). The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-κB signalling pathways. Oncogene 29: 4307–4316.
Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF et al. (2009). A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4: 255–264.
Noushmehr H, Weisenberger DJ, Diefes K, Diefes K, Phillips HS, Pujara K et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510–522.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
Reeves N, Posakony JW . (2005). Genetic programs activated by proneural proteins in the developing Drosophila PNS. Dev Cell 8: 413–425.
Richter AM, Pfeifer GP, Dammann RH . (2009). The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 1796: 114–128.
Rodriguez-Viciana P, Sabatier C, McCormick F . (2004). Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 24: 4943–4954.
Schagdarsurengin U, Richter AM, Wöhler C, Dammann RH . (2009). Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics 4: 571–576.
Sherwood V, Manbodh R, Sheppard C, Chalmers AD . (2008). RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell 19: 1772–1782.
Sherwood V, Recino A, Jeffries A, Ward A, Chalmers AD . (2009). The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. Biochem J 425: 303–311.
Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM et al. (2005). Tumor susceptibility of Rassf1a knockout mice. Cancer Res 65: 92–98.
van der Weyden L, Tachibana KK, Gonzalez MA, Adams DJ, Ng BL, Petty R et al. (2005). The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol 25: 8356–8367.
Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W et al. (2010). MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6: 39–51.
Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D et al. (2010). CpG island hypermethylation in human astrocytomas. Cancer Res 70: 2718–2727.
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. (2009a). IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765–773.
Yan H, Bigner DD, Velculescu V, Parsons DW . (2009b). Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 69: 9157–9159.
Acknowledgements
We thank Dr Reinhard Dammann for providing the RASSF10 construct. F Latif laboratory funded in part by Breast Cancer Campaign, CRUK and Sport Aiding Medical Research for Kids (SPARKS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Hill, V., Underhill-Day, N., Krex, D. et al. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 30, 978–989 (2011). https://doi.org/10.1038/onc.2010.471
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.471
Keywords
This article is cited by
-
Neuroinflammation regulates the balance between hippocampal neuron death and neurogenesis in an ex vivo model of thiamine deficiency
Journal of Neuroinflammation (2022)
-
RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice
Oncogene (2020)
-
Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma
Oncogenesis (2016)
-
The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer
Tumor Biology (2016)
-
Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas
BMC Cancer (2014)